Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of immunotherapy

• Publication date

  2016-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/CJI.0000000000000126PMID 27163741PMCID PMC5847343
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.

  2015cited by this paper
• Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

  2015cited by this paper
• Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

  2015cited by this paper
• Nature of Tumor Control by Permanently and Transiently Modified GD2 Chimeric Antigen Receptor T Cells in Xenograft Models of Neuroblastoma

  2014cited by this paper
• TETHERED IL-15 TO AUGMENT THE THERAPEUTIC POTENTIAL OF T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR: MAINTAINING MEMORY POTENTIAL, PERSISTENCE, AND ANTITUMOR ACTIVITY

  2014cited by this paper
• Using the molecular classification of glioblastoma to inform personalized treatment

  2014cited by this paper
• Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• A new approach to gene therapy using Sleeping Beauty to genetically modify clinical‐grade T cells to target CD19

  2014cited by this paper
• Activation and Propagation of Tumor-infiltrating Lymphocytes on Clinical-grade Designer Artificial Antigen-presenting Cells for Adoptive Immunotherapy of Melanoma

  2014cited by this paper
• Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor.

  2013cited by this paper
• Regimen-Specific Effects of RNA-Modified Chimeric Antigen Receptor T Cells in Mice with Advanced Leukemia

  2013cited by this paper
• Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.

  2013cited by this paper
• EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss

  2013cited by this paper
• Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma

  2013cited by this paper
• Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies

  2013cited by this paper
• CD4 T-cell immunotherapy for chronic viral infections and cancer.

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy

  2012cited by this paper
• Standardizing immunophenotyping for the Human Immunology Project

  2012cited by this paper
• Adoptive T-cell therapy improves treatment of canine non–Hodgkin lymphoma post chemotherapy

  2012cited by this paper
• Glioblastoma survival in the United States before and during the temozolomide era

  2012cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.

  2010cited by this paper
• Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

  2010cited by this paper
• HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors

  2010cited by this paper
• Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: Differing impact on CD8 T cell phenotype and responsiveness to restimulation

  2010cited by this paper
• Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells.

  2009cited by this paper
• Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells

  2009cited by this paper
• Establishment and Characterization of a Cell Based Artificial Antigen-Presenting Cell for Expansion and Activation of CD8+ T Cells Ex Vivo

  2008cited by this paper
• Chimeric Receptor mRNA Transfection as a Tool to Generate Antineoplastic Lymphocytes

  2008cited by this paper
• Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines

  2008cited by this paper
• Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.

  2008cited by this paper
• Adoptive immunotherapy: good habits instilled at youth have long-term benefits

  2008cited by this paper
• Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.

  2007cited by this paper
• T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

  2007cited by this paper
• Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma

  2006cited by this paper
• CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

  2006cited by this paper
• Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro.

  2006cited by this paper
• Epidermal Growth Factor Receptor–Mediated Signal Transduction in the Development and Therapy of Gliomas

  2006cited by this paper
• Human Naive CD8 T Cells Down-Regulate Expression of the WNT Pathway Transcription Factors Lymphoid Enhancer Binding Factor 1 and Transcription Factor 7 (T Cell Factor-1) following Antigen Encounter In Vitro and In Vivo1

  2006cited by this paper
• The natural history of EGFR and EGFRvIII in glioblastoma patients

  2005cited by this paper
• Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme.

  2005cited by this paper
• Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients

  2005cited by this paper
• Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells.

  2003cited by this paper
• Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help

  2003cited by this paper
• Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition.

  2003cited by this paper
• Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB

  2002cited by this paper
• CD8 lethargy in the absence of CD4 help

  2002cited by this paper
• Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.

  2000cited by this paper
• Cluster analysis and display of genome-wide expression patterns.

  1998cited by this paper
• University of Texas Health Science Center at Houston.

  1983cited by this paper
• Transfer Therapy Cancer Regression in Patients Receiving Cell Lymphocyte Clonotypes Correlates with Cutting Edge: Persistence of Transferred

  year unknowncited by this paper

• Self-amplifying RNA-based CAR T cell therapy with enhanced duration and multi-genic logic function

  2026cites this paper
• mRNA-engineered T lymphocytes secreting bispecific T cell engagers with therapeutic potential in solid tumors

  2025cites this paper
• Preclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma

  2025cites this paper
• The paths toward non-viral CAR-T cell manufacturing: A comprehensive review of state-of-the-art methods.

  2024cites this paper
• Augmenting the landscape of chimeric antigen receptor T-cell therapy

  2024cites this paper
• Generation of CAR-TSCM: CAR-T with super clutch.

  2024cites this paper
• Oxidized mRNA Lipid Nanoparticles for In Situ Chimeric Antigen Receptor Monocyte Engineering

  2024cites this paper
• RNA-Based Therapeutic Technology

  2023cites this paper
• Multifunctional mRNA-based CAR T cells display promising anti-tumor activity against glioblastoma.

  2022cites this paper
• Advances in mRNA-based drug discovery in cancer immunotherapy

  2021cites this paper
• Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development

  2021cites this paper
• Clinical and immunological effects of mRNA vaccines in malignant diseases

  2021influential citation
• Advances in Development of mRNA-Based Therapeutics.

  2020cites this paper
• Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy

  2020cites this paper
• Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer

  2020cites this paper
• CAR T cells and checkpoint inhibition for the treatment of glioblastoma

  2020influential citation
• Membrane-proximal external region is a superior target for mediating effector activity of HIV-1 specific chimeric antigen receptor modified T cells

  2020cites this paper
• Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR.

  2020cites this paper
• In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update

  2020influential citation
• Immuntherapien zur Behandlung der chronischen Hepatitis-B-Virusinfektion – eine Übersicht unter besonderer Berücksichtigung von CAR-T-Zellen

  2020cites this paper
• [Immunotherapies for the treatment of chronic hepatitis B virus infections-an overview with a focus on CAR T cells].

  2020cites this paper
• RNA-electroporated T cells for cancer immunotherapy

  2020cites this paper
• CAR-T Cells: Future Perspectives

  2019cites this paper
• The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy.

  2019cites this paper
• Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding

  2019cites this paper
• RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors.

  2019cites this paper
• Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy

  2019cites this paper
• Determinants of response and resistance to CAR T cell therapy.

  2019cites this paper
• Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.

  2018cites this paper
• Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side

  2017cites this paper
• Steering CAR T cells to distinguish friend from foe

  2017cites this paper
• History and current state of immunotherapy in glioma and brain metastasis

  2017cites this paper
• Chimeric antigen receptor T-cell therapy for glioblastoma.

  2017cites this paper
• Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors

  2016cites this paper